OBJECTIVE: To study the incidence and pattern of neurologic disorders in a large cohort of HIV-positive men, compared with HIV-negative men, in the era of highly active antiretroviral therapy (HAART). METHODS: The Multicenter AIDS Cohort Study is a prospective study of men who have sex with men enrolled in 4 cities in the United States. We compared HIV-positive vs HIV-negative men for incidence and category of neurologic diagnoses in the HAART era (July 1, 1996, to last known follow-up or death, on or before July 1, 2011). RESULTS: There were 3,945 participants alive during the HAART era (2,083 HIV negative, 1,776 HIV positive, and 86 who became infected with HIV during the study period) including 3,427 who were older than 40 years of age. Median age at first neurologic diagnosis among all participants alive in the HAART era was lower in HAART-treated HIV-positive vs HIV-negative men (48 vs 57 years of age, p < 0.001). Incidence of neurologic diagnoses was higher in HAART-treated HIV-positive vs HIV-negative men (younger than 40 years: 11.4 vs 0 diagnoses per 1,000 person-years [p < 0.001]; 40-49 years: 11.6 vs 2.0 [p < 0.001]; 50-60 years: 15.1 vs 3.0 [p < 0.001]; older than 60 years: 17.0 vs 5.7 [p < 0.01]). Excess neurologic disease was found in the categories of nervous system infections (p < 0.001), dementia (p < 0.001), seizures/epilepsy (p < 0.01), and peripheral nervous system disorders (p < 0.001), but not stroke (p = 0.60). CONCLUSIONS: HIV-positive men receiving HAART have a higher burden of neurologic disease than HIV-negative men and develop neurologic disease at younger ages.
OBJECTIVE: To study the incidence and pattern of neurologic disorders in a large cohort of HIV-positive men, compared with HIV-negative men, in the era of highly active antiretroviral therapy (HAART). METHODS: The Multicenter AIDS Cohort Study is a prospective study of men who have sex with men enrolled in 4 cities in the United States. We compared HIV-positive vs HIV-negative men for incidence and category of neurologic diagnoses in the HAART era (July 1, 1996, to last known follow-up or death, on or before July 1, 2011). RESULTS: There were 3,945 participants alive during the HAART era (2,083 HIV negative, 1,776 HIV positive, and 86 who became infected with HIV during the study period) including 3,427 who were older than 40 years of age. Median age at first neurologic diagnosis among all participants alive in the HAART era was lower in HAART-treated HIV-positive vs HIV-negative men (48 vs 57 years of age, p < 0.001). Incidence of neurologic diagnoses was higher in HAART-treated HIV-positive vs HIV-negative men (younger than 40 years: 11.4 vs 0 diagnoses per 1,000 person-years [p < 0.001]; 40-49 years: 11.6 vs 2.0 [p < 0.001]; 50-60 years: 15.1 vs 3.0 [p < 0.001]; older than 60 years: 17.0 vs 5.7 [p < 0.01]). Excess neurologic disease was found in the categories of nervous system infections (p < 0.001), dementia (p < 0.001), seizures/epilepsy (p < 0.01), and peripheral nervous system disorders (p < 0.001), but not stroke (p = 0.60). CONCLUSIONS: HIV-positive men receiving HAART have a higher burden of neurologic disease than HIV-negative men and develop neurologic disease at younger ages.
Authors: N Sacktor; R H Lyles; R Skolasky; C Kleeberger; O A Selnes; E N Miller; J T Becker; B Cohen; J C McArthur Journal: Neurology Date: 2001-01-23 Impact factor: 9.910
Authors: R Detels; L Jacobson; J Margolick; O Martinez-Maza; A Muñoz; J Phair; C Rinaldo; S Wolinsky Journal: Public Health Date: 2011-12-27 Impact factor: 2.427
Authors: Edward J Mills; Celestin Bakanda; Josephine Birungi; Keith Chan; Nathan Ford; Curtis L Cooper; Jean B Nachega; Mark Dybul; Robert S Hogg Journal: Ann Intern Med Date: 2011-07-18 Impact factor: 25.391
Authors: V Valcour; C Shikuma; B Shiramizu; M Watters; P Poff; O Selnes; P Holck; J Grove; N Sacktor Journal: Neurology Date: 2004-09-14 Impact factor: 9.910
Authors: Jordan E Lake; Mikhail Popov; Wendy S Post; Frank J Palella; Ned Sacktor; Eric N Miller; Todd T Brown; James T Becker Journal: J Neurovirol Date: 2016-12-15 Impact factor: 2.643
Authors: Mahmoud A AbdelRazek; Jose Gutierrez; David Mampre; Anna Cervantes-Arslanian; Cora Ormseth; Diogo Haussen; Kiran T Thakur; Jennifer L Lyons; Bryan R Smith; Owen O'Connor; Joshua Z Willey; Farrah J Mateen Journal: Stroke Date: 2018-01 Impact factor: 7.914
Authors: Derek K Ng; Lisa P Jacobson; Todd T Brown; Frank J Palella; Jeremy J Martinson; Robert Bolan; Edgar R Miller; George J Schwartz; Alison G Abraham; Michelle M Estrella Journal: AIDS Date: 2014-01-28 Impact factor: 4.177
Authors: Farrah J Mateen; Wendy S Post; Ned Sacktor; Alison G Abraham; James T Becker; Bryan R Smith; Roger Detels; Eileen Martin; John P Phair; Russell T Shinohara Journal: Neurology Date: 2013-11-08 Impact factor: 9.910
Authors: David P Sheppard; Steven Paul Woods; Mark W Bondi; Paul E Gilbert; Paul J Massman; Katie L Doyle Journal: Clin Neuropsychol Date: 2015-08-26 Impact factor: 3.535
Authors: Jose Gutierrez; Khaled Menshawy; Marco Gonzalez; James Goldman; Mitchell S V Elkind; Randolph Marshall; Susan Morgello Journal: AIDS Date: 2016-01-28 Impact factor: 4.177